pharma · Solid Tumors · Primary Dysmenorrhea
Topiloric/Uriadec drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Topiloric/Uriadec drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Topiloric/Uriadec's portfolio. Molecular target: Epidermal growth factor receptor.
US regulatory status: approved. Mechanism: Unknown.
Antiinfectives for systemic use (J07) compound in Topiloric/Uriadec's portfolio.
Development asset linked to Topiloric/Uriadec in public FDA and regional records.
Development asset linked to Topiloric/Uriadec in public FDA and regional records.
Development asset linked to Topiloric/Uriadec in public FDA and regional records.
Development asset linked to Topiloric/Uriadec in public FDA and regional records.